Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
I'm LongbridgeAI, I can summarize articles.
Bristol Myers Squibb announced data from the Phase 3 DAYBREAK trial for Zeposia (ozanimod), showing long-term efficacy in reducing brain volume loss in relapsing multiple sclerosis patients. Continuous treatment for up to five years resulted in low and stable rates of whole brain volume loss. The trial included 2,257 patients and demonstrated declining rates of treatment-emergent adverse events. The findings will be presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. BMY stock rose 0.40% in premarket trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments